X4 Pharmaceuticals, Inc. XFOR
3.01
0.01
0.33%
as of 25 Sep
- Market cap
- $297.4M
- P/E
- 0.0×
Follow XFOR
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
37.23 | 57.86 | 4.82 | 4.36 | |
P/FCF ratio |
37.02 | 59.10 | 10.54 | 0.00 | |
P/Operating CF |
(28.38) | (26.61) | (10.90) | (5.32) | |
P/B ratio |
3.80 | 3.10 | 0.91 | 2.40 | |
Price to Tangible BV |
4.72 | 3.67 | 1.06 | 4.25 | |
EV/Sales |
29.00 | 40.51 | (0.19) | 3.02 | |
EV/EBITDA |
0.00 | 0.00 | 0.08 | 0.00 | |
EV/Operating CF |
(5.49) | (3.93) | 0.08 | (1.00) | |
EV/FCF |
28.84 | 41.38 | (0.42) | (72.68) | |
Quick Ratio |
10.84 | 9.88 | 9.84 | 5.27 | |
Current Ratio |
11.30 | 10.18 | 10.16 | 5.65 | |
Net Debt/EBITDA |
8.52 | 7.83 | 7.53 | 1.69 | |
Debt/Assets |
30.33% | 28.31% | 26.27% | 46.51% | |
Debt/Equity |
0.49 | 0.45 | 0.41 | 1.23 | |
Asset Turnover |
0.09 | 0.05 | 0.16 | 0.20 | |
Operating CF/Net income |
1.29 | 0.97 | 0.65 | 0.93 | |
Capex/Depreciation |
(5.01) | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
171.24% | 570.53% | 721.22% | 982.27% | |
Selling, General and Administrative Expense of Revenue |
96.54% | 257.24% | 287.46% | 656.43% | |
Intangible Assets out of Total Assets |
0.12 | 0.10 | 0.09 | 0.16 | |
Share Based Compensation of Revenue |
35.04% | 89.11% | 88.43% | 43.06% | |
Graham Net Nets |
0.21 | 0.27 | 0.93 | 0.21 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(25.70%) | (109.93%) | (108.50%) | (296.08%) | |
Free Cash Flow Yield |
2.70% | 1.69% | 9.49% | (0.95%) | |
Revenue per Share |
0.07 | 0.02 | 0.06 | 0.04 | |
Operating CF per Share |
(0.16) | (0.16) | (0.37) | (0.64) | |
Capex per Share |
(0.04) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.20) | (0.16) | (0.37) | (0.64) | |
Cash per Share |
1.65 | 1.85 | 5.98 | 2.82 | |
Shareholders Equity per Share |
1.23 | 1.33 | 4.40 | 1.42 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.23 | 1.33 | 4.40 | 1.42 | |
Free Cash Flow |
(25.79) | (19.60) | (15.53) | (27.82) | |
Working Capital |
199.49 | 218.21 | 235.82 | 109.30 | |
Capital Expenditures |
(5.00) | — | 0.00 | 0.00 | |
Net Current Asset Value |
121.25 | 140.15 | 157.41 | 30.87 | |
EV/EBIT |
0.00 | 0.00 | 0.08 | 0.00 | |
Capex to Sales |
0.57 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(183.48%) | (747.45%) | (931.66%) | (1,689.24%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.96 | 1.14 | 1.14 | 1.34 | |
Average Payables |
5.82 | 8.09 | 7.16 | 6.82 | |
Average Inventory |
4.34 | 3.86 | 3.65 | 3.26 | |
Average Assets |
179.12 | 200.15 | 218.45 | 170.86 | |
Average Common Equity |
79.71 | 95.70 | 104.22 | 60.62 |
Columns are period end dates